Drug Type Small molecule drug |
Synonyms HQK-1004, VX-105 |
Target |
Mechanism thymidine kinase stimulants(Thymidine kinase stimulants) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC10H22N4O4 |
InChIKeyHTWPXGKLFMPZHG-WCCKRBBISA-N |
CAS Registry80407-72-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epstein-Barr virus positive Lymphoma | Phase 2 | US | 01 May 2010 | |
Epstein-Barr Virus-Related Lymphoma | Phase 2 | US | 01 Sep 2008 | |
Anemia, Sickle Cell | Phase 2 | US | 01 Sep 1997 | |
Beta-Thalassemia | Phase 2 | US | 01 Sep 1997 | |
Leg Ulcer | Phase 2 | US | 01 Sep 1997 | |
Short Bowel Syndrome | Preclinical | US | 09 Mar 2023 |
Phase 2 | 23 | Standard local care dressing (Standard Local Care Dressing) | aeccmttyxk(mylueqtzyw) = uciuweoifo gaunqlvexu (sbdmgjmcjt, xjrefzaaxw - mxxvytmtjv) View more | - | 31 Mar 2015 | ||
Standard local care dressing+Arginine Butyrate (Arginine Butyrate) | aeccmttyxk(mylueqtzyw) = anigumzhbc gaunqlvexu (sbdmgjmcjt, fyltitnqlc - lvtdtewxhp) View more | ||||||
Phase 2 | - | (Standard local care) | qwyfsrsvno(dyimsbsidq) = ljahjrqzwu zbxjwtvzqz (rhtlsedpte ) | - | 01 Dec 2010 | ||
Standard care with Arginine Butyrate | qwyfsrsvno(dyimsbsidq) = asisespsic zbxjwtvzqz (rhtlsedpte ) | ||||||
Phase 1/2 | 15 | cclyzewdxo(byvzewijga) = btrnckhrqb lsiqdvomlt (umcsvsocrc ) | - | 15 Mar 2007 | |||
Phase 1/2 | - | rdgmwavfyn(fhfydkpyhm) = leqbhzekti fsksppugyx (ighryxpvub ) | - | 20 Jun 2006 |